Precision System Science Co.,Ltd (7707) AI Stock Analysis

• Market Cap: ¥6.67B
• Dividend Yield: N/A
• Average Volume (3M): 159.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 17.91%
• EPS Growth: 77.32%
• Country: JP
• Employees: 158
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 27,666,900
• 10 Day Avg. Volume: 171,040
• 30 Day Avg. Volume: 159,673
• PEG Ratio: 0.28
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 127.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ¥235.00 ▲(26.34% Upside)
• Action: Reiterated Date: 10/02/25
• Date: Action: Reiterated 10/02/25

The overall stock score of 45 reflects significant challenges in financial performance, particularly in profitability and cash flow management. Technical analysis indicates weak momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low score, highlighting the need for substantial improvements in operational efficiency and financial health.

Positive Factors

Revenue recovery and growth

A reported ~20.8% revenue growth indicates demand recovery for lab automation products. Sustained top-line expansion over multiple quarters can enable scale economies, support higher utilization of installed equipment, and provide a base for durable margin improvement if maintained.

Specialized lab-automation business model

The company’s focus on precision automation, consumables and support services creates an installed-base business with recurring aftermarket revenue and higher switching costs. This niche positioning supports long-term customer stickiness and potential steady service revenue streams.

Moderate leverage and reasonable equity base

Stable, moderate leverage gives the company financial flexibility to fund incremental capex or product development without over-reliance on external financing. A reasonable equity base reduces solvency risk and supports longer-term investment in R&D and commercialization.

Negative Factors

Persistent negative profitability

Consistent negative operating and net margins indicate core profitability issues and operational inefficiencies. Persistent losses constrain retained earnings, limit reinvestment capacity, and make it harder to sustainably fund growth or deliver positive returns to shareholders over the medium term.

Volatile and weak cash conversion

Inconsistent operating cash flows and poor conversion of earnings to cash reduce the company’s ability to self-fund R&D, service debt, and support working capital. This increases reliance on external financing and raises execution risk during industry slowdowns.

Operational inefficiencies and historical revenue decline

Historical revenue declines and ongoing operational inefficiencies point to execution and competitiveness issues. Even with recent recovery, structural fixes are needed to restore margins and cash flow reliability, which may take multiple quarters to implement and realize.

Precision System Science Co.,Ltd Business Overview & Revenue Model

Company Description

Precision System Science Co., Ltd., together with its subsidiaries, develops, manufactures, and sells automated systems/instruments, other physicochemical instruments, software, and other products in Japan and internationally. The company manufactures and sells plastic consumables, which are used in automated systems/instruments, as well as reagents; and automated nucleic acid extraction and veterinary biochemical analysis systems. It also offers geneLEAD, an instrument for molecular testing; and engages in the research and development, and practical application of in vitro diagnosis testing market, including genetic and protein tests. Precision System Science Co., Ltd. was founded in 1985 and is headquartered in Matsudo, Japan.

How the Company Makes Money

Precision System Science Co., Ltd. generates revenue by designing, manufacturing, and selling automated laboratory systems and instruments. Key revenue streams include the sale of DNA extraction and sample preparation systems, which are integral to various diagnostic and research applications in the life sciences field. The company also earns from the sale of consumables and reagents, which are used in conjunction with their systems. Additionally, Precision System Science engages in strategic partnerships and collaborations with other companies and research institutions, enhancing their market reach and contributing to their earnings.

Precision System Science Co.,Ltd Financial Statement Overview

Summary

Precision System Science Co., Ltd. faces significant challenges in profitability and cash flow management. Revenue recovery is evident, but operational inefficiencies and poor cash generation from operations remain concerns. The balance sheet shows moderate leverage, but profitability issues persist.

Income Statement

The company has experienced a decline in revenue over the past few years, with a slight recovery in the latest period. Gross profit margins have been inconsistent, and net profit margins have been negative, indicating ongoing profitability challenges. The EBIT and EBITDA margins have also been negative, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has been relatively stable, indicating moderate leverage. However, the return on equity has been negative in recent years, reflecting poor profitability. The equity ratio suggests a reasonable level of equity financing relative to total assets.

Cash Flow

Operating cash flow has been volatile, with recent improvements. Free cash flow growth has been positive, but the free cash flow to net income ratio indicates challenges in converting profits into cash. The operating cash flow to net income ratio has been inconsistent, reflecting cash flow management issues.

Breakdown	Jun 2025	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	4.69B	3.98B	7.43B	9.30B	5.07B
Gross Profit	1.38B	950.38M	2.49B	3.10B	1.56B
EBITDA	10.06M	-661.75M	740.33M	1.16B	18.83M
Net Income	-253.10M	-1.12B	45.34M	795.99M	-114.28M
Balance Sheet
Total Assets	4.94B	6.40B	11.41B	11.57B	6.44B
Cash, Cash Equivalents and Short-Term Investments	1.04B	1.92B	2.76B	4.04B	2.11B
Total Debt	564.21M	1.37B	4.02B	3.69B	1.01B
Total Liabilities	1.18B	2.25B	4.90B	4.99B	2.12B
Stockholders Equity	3.76B	4.14B	6.51B	6.58B	4.32B
Cash Flow
Free Cash Flow	43.24M	-130.81M	-1.38B	-2.09B	-251.76M
Operating Cash Flow	95.83M	-106.80M	869.16M	-280.97M	-21.45M
Investing Cash Flow	-8.24M	2.06B	-2.29B	-1.81B	-214.08M
Financing Cash Flow	-910.82M	-2.51B	93.73M	4.00B	510.79M

Precision System Science Co.,Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 186.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7707, the sentiment is Positive. The current price of 186 is below the 20-day moving average (MA) of 236.15, below the 50-day MA of 219.58, and below the 200-day MA of 203.06, indicating a bullish trend. The MACD of 5.00 indicates Positive momentum. The RSI at 55.01 is Neutral, neither overbought nor oversold. The STOCH value of 65.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7707.

Precision System Science Co.,Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥15.04B	41.33	―	―	12.91%	37.96%
3386	70 Outperform	¥7.94B	23.54	―	4.57%	6.49%	-32.16%
6090	67 Neutral	¥4.16B	19.57	―	2.35%	-0.82%	-21.75%
4582	52 Neutral	¥8.74B	-1.54	―	―	-50.27%	-3.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7707	45 Neutral	¥6.67B	-187.29	―	―	17.91%	77.32%